AUS
NZ
UK
CA
USA
IND
Highlights
- Iterum Therapeutics receives FDA approval for its new drug, ORLYNVAH.
- ORLYNVAH targets uncomplicated urinary tract infections in adult women.
- The approval marks Iterum’s first FDA-approved product.
Iterum Therapeutics plc, a pharmaceutical company listed on NASDAQ as (NASDAQ:ITRM), has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its new drug application for ORLYNVAH. This approval is specific to the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have few or no alternative oral antibacterial treatment options available.
Significance of ORLYNVAH Approval
ORLYNVAH, a combination of sulopenem etzadroxil and probenecid, is the first product approved by the FDA for Iterum Therapeutics. This approval signifies an important development for the company, expanding its ability to provide treatment options in the antibacterial market. As the first oral penem antibiotic approved in the U.S., ORLYNVAH is positioned to offer a new alternative for adult women experiencing uUTIs, especially those who have limited choices in current treatments.
The introduction of this new drug underscores the need for innovative solutions in the battle against antimicrobial resistance. The approval of ORLYNVAH is seen as a significant step towards addressing the challenges associated with such infections and providing healthcare professionals with more options for their patients.
Clinical Trials and Efficacy
The FDA’s approval of ORLYNVAH is supported by an extensive clinical development program. This program included two pivotal Phase 3 clinical trials named SURE 1 and REASSURE. The trials assessed the safety and effectiveness of ORLYNVAH compared to other established antibacterial treatments.
In the SURE 1 trial, ORLYNVAH demonstrated its superiority over ciprofloxacin when treating fluoroquinolone-resistant infections. Meanwhile, the REASSURE trial confirmed that ORLYNVAH was not only non-inferior but also statistically superior to Augmentin in the population susceptible to Augmentin. These trials showcased that ORLYNVAH is generally well tolerated, providing a promising solution for patients who have limited treatment options for uUTIs.
A Step Towards a New Market Opportunity
The approval of ORLYNVAH has not only expanded Iterum’s product portfolio but also opens up new opportunities within the uUTI market, particularly for underserved patients. The company has expressed its intention to maximize the value of ORLYNVAH through strategic transactions, aiming to increase its impact and reach in the healthcare sector. Iterum’s CEO emphasized the importance of this achievement, acknowledging the collaborative efforts of patients, researchers, and team members who contributed to the development of this product.
ORLYNVAH stands as a testament to the advancements in addressing antibiotic resistance and providing new, effective treatments. With its approval, Iterum Therapeutics is set to make a significant impact in the field of infectious disease management, ensuring better outcomes for those affected by challenging bacterial infections.
